» Articles » PMID: 38315992

Polyploidy in Cancer: Causal Mechanisms, Cancer-Specific Consequences, and Emerging Treatments

Overview
Journal Mol Cancer Ther
Date 2024 Feb 5
PMID 38315992
Authors
Affiliations
Soon will be listed here.
Abstract

Drug resistance is the major determinant for metastatic disease and fatalities, across all cancers. Depending on the tissue of origin and the therapeutic course, a variety of biological mechanisms can support and sustain drug resistance. Although genetic mutations and gene silencing through epigenetic mechanisms are major culprits in targeted therapy, drug efflux and polyploidization are more global mechanisms that prevail in a broad range of pathologies, in response to a variety of treatments. There is an unmet need to identify patients at risk for polyploidy, understand the mechanisms underlying polyploidization, and to develop strategies to predict, limit, and reverse polyploidy thus enhancing efficacy of standard-of-care therapy that improve better outcomes. This literature review provides an overview of polyploidy in cancer and offers perspective on patient monitoring and actionable therapy.

Citing Articles

Integrative genomic analyses combined with molecular dynamics simulations reveal the impact of deleterious mutations of Bcl-2 gene on the apoptotic machinery and implications in carcinogenesis.

Elamin G, Zhang Z, Dwarka D, Kasumbwe K, Mellem J, Mkhwanazi N Front Genet. 2025; 15:1502152.

PMID: 39840282 PMC: 11747654. DOI: 10.3389/fgene.2024.1502152.


Aurora B inhibition induces hyper-polyploidy and loss of long-term proliferative potential in RB and p53 defective cells.

Vora S, Chatterjee S, Andrew A, Kumar R, Proctor M, Zeng Z Cell Death Dis. 2025; 16(1):7.

PMID: 39779678 PMC: 11711630. DOI: 10.1038/s41419-024-07329-7.

References
1.
Hsu C, Huang Y, Hsieh C, Wu C, Shen T . JNK Inactivation Induces Polyploidy and Drug-Resistance in Coronarin D-Treated Osteosarcoma Cells. Molecules. 2018; 23(9). PMC: 6225306. DOI: 10.3390/molecules23092121. View

2.
Garcia-Saez I, Skoufias D . Eg5 targeting agents: From new anti-mitotic based inhibitor discovery to cancer therapy and resistance. Biochem Pharmacol. 2020; 184:114364. DOI: 10.1016/j.bcp.2020.114364. View

3.
Islam S, Paek A, Hammer M, Rangarajan S, Ruijtenbeek R, Cooke L . Drug-induced aneuploidy and polyploidy is a mechanism of disease relapse in MYC/BCL2-addicted diffuse large B-cell lymphoma. Oncotarget. 2018; 9(89):35875-35890. PMC: 6267596. DOI: 10.18632/oncotarget.26251. View

4.
Mahadevan D, Rogers G . Janus Face of Drug-Induced Tetraploidy in Non-Hodgkin Lymphoma. Trends Cancer. 2020; 6(8):627-630. DOI: 10.1016/j.trecan.2020.03.009. View

5.
Islam S, Qi W, Morales C, Cooke L, Spier C, Weterings E . Disruption of Aneuploidy and Senescence Induced by Aurora Inhibition Promotes Intrinsic Apoptosis in Double Hit or Double Expressor Diffuse Large B-cell Lymphomas. Mol Cancer Ther. 2017; 16(10):2083-2093. PMC: 6574129. DOI: 10.1158/1535-7163.MCT-17-0089. View